trials of interferon beta-1b

Last reviewed 01/2018

The first trials of interferon in multiple sclerosis used recombinant interferon beta-1b.

Interferon beta-1b differs from the human cytokine in two ways:

  • has an aminoacid substitution at one position
  • is non-glycosylated

Patients treated with the high dose of 8 MIU subcutanesouly on alternate days had the following significant benefits:

  • 34% reduction in the relapse rate
  • marked reduction in disease burden as assessed by T2-weighted MRI imaging after two years

The trials with interferon beta-1b did not show a significant reduction in accumulated disability.